{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/pricing-and-reimbursement-germany-glance#webpage",
"url": "https://www.fortrea.com/insights/pricing-and-reimbursement-germany-glance",
"name": "Pricing and reimbursement in Germany: At a glance",
"description": "This Fortrea infosheet explores pricing and reimbursement in Germany and the strategic considerations involved in pharmaceutical market access and reimbursement decision-making. The content focuses on processes related to AMNOG assessment, reimbursement pathways, evidence requirements, benefit evaluation, and pricing negotiations within the German pharmaceutical landscape. The infosheet highlights challenges associated with demonstrating product value, aligning clinical evidence with reimbursement expectations, and navigating Germany’s evolving pricing and reimbursement framework. Fortrea outlines strategic approaches designed to support pharmaceutical companies through market access planning, evidence development, reimbursement strategy, and regulatory considerations that influence pricing and reimbursement outcomes in Germany. By integrating reimbursement planning with evidence generation and market access strategy, the infosheet provides insights into navigating pharmaceutical pricing and reimbursement processes within the German healthcare environment."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Pricing and reimbursement in Germany: At a glance",
"item": "https://www.fortrea.com/insights/pricing-and-reimbursement-germany-glance"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/pricing-and-reimbursement-germany-glance#infosheet",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/pricing-and-reimbursement-germany-glance#webpage"
},
"headline": "Pricing and reimbursement in Germany: At a glance",
"description": "This Fortrea infosheet explores pricing and reimbursement in Germany and the strategic considerations involved in pharmaceutical market access and reimbursement decision-making. The content focuses on processes related to AMNOG assessment, reimbursement pathways, evidence requirements, benefit evaluation, and pricing negotiations within the German pharmaceutical landscape. The infosheet highlights challenges associated with demonstrating product value, aligning clinical evidence with reimbursement expectations, and navigating Germany’s evolving pricing and reimbursement framework. Fortrea outlines strategic approaches designed to support pharmaceutical companies through market access planning, evidence development, reimbursement strategy, and regulatory considerations that influence pricing and reimbursement outcomes in Germany. By integrating reimbursement planning with evidence generation and market access strategy, the infosheet provides insights into navigating pharmaceutical pricing and reimbursement processes within the German healthcare environment.",
"genre": "Info Sheet",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2025-03/pricing-and-reimbursement-in-germany-at-a-glance.jpg"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2025-03-17",
"dateModified": "2025-03-17",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2025-03/pricing-and-reimbursement-in-germany-at-a-glance.pdf",
"encodingFormat": "application/pdf"
}
}
]
}